Lipinski's rule of five: Difference between revisions

Latest revision as of 11:33, 15 February 2025

Overview[edit]

Lipinski's Rule of Five is a set of guidelines used to evaluate the druglikeness of a chemical compound. It predicts the likelihood of a compound being an orally active drug in humans. The rule was formulated by Christopher A. Lipinski in 1997 and is widely used in medicinal chemistry and pharmacology.

The Rule of Five[edit]

The rule is based on the observation that most orally active drugs have certain physicochemical properties. According to Lipinski's Rule of Five, a compound is more likely to be orally active if it meets the following criteria:

The compound has no more than 5 hydrogen bond donors (the total number of nitrogen–hydrogen and oxygen–hydrogen bonds).
The compound has no more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms).
The molecular weight of the compound is less than 500 daltons.
The compound has a log P (octanol-water partition coefficient) that does not exceed 5.

These criteria are not strict rules but rather guidelines that help in the design and evaluation of potential drug candidates.

Importance in Drug Discovery[edit]

Lipinski's Rule of Five is crucial in the early stages of drug discovery and development. It helps researchers identify compounds with favorable pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME). Compounds that violate more than one of these rules are less likely to be orally active.

Limitations[edit]

While Lipinski's Rule of Five is a valuable tool, it has limitations. It does not account for all factors influencing drug absorption and bioavailability, such as P-glycoprotein efflux and metabolic stability. Additionally, some drugs that violate the rule are still effective, such as antibiotics, antifungals, and natural products.

Example: Omeprazole[edit]

Omeprazole, a proton pump inhibitor, is an example of a drug that follows Lipinski's Rule of Five.

An example of a drug that adheres to Lipinski's Rule of Five is omeprazole, a widely used proton pump inhibitor for treating gastroesophageal reflux disease (GERD). Omeprazole has a molecular weight of 345.42 daltons, 1 hydrogen bond donor, 4 hydrogen bond acceptors, and a log P of 3.3, making it compliant with the rule.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Lipinski's Rule of Five''' is a set of criteria used to predict the [[oral bioavailability]] of a potential [[drug compound]] in humans. It was formulated by Christopher A. Lipinski in 1997, based on the observation of existing drug molecules. The rule is often used in [[pharmacology]] and [[medicinal chemistry]] to guide the early stages of [[drug discovery]] and development. According to Lipinski's Rule of Five, a compound is more likely to have good oral bioavailability if it does not violate more than one of the following criteria:
+{{DISPLAYTITLE:Lipinski's Rule of Five}}
-* No more than 5 hydrogen bond donors ([[nitrogen]] or [[oxygen]] atoms with one or more hydrogen atoms)
+== Overview ==
-* No more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms)
+'''Lipinski's Rule of Five''' is a set of guidelines used to evaluate the druglikeness of a chemical compound. It predicts the likelihood of a compound being an orally active drug in humans. The rule was formulated by [[Christopher A. Lipinski]] in 1997 and is widely used in [[medicinal chemistry]] and [[pharmacology]].
-* A [[molecular mass]] less than 500 daltons
-* An [[octanol-water partition coefficient]] ([[logP]]) less than 5
-== Background ==
+== The Rule of Five ==
-The development of new drugs is a complex, time-consuming, and costly process. Identifying compounds with suitable pharmacokinetic properties, including oral bioavailability, is a critical step in this process. Oral bioavailability is influenced by several factors, including solubility, permeability, and stability. Lipinski's Rule of Five serves as a heuristic tool to evaluate the drug-likeness of compounds based on their physical and chemical properties, potentially reducing the time and resources spent on unsuitable candidates.
+The rule is based on the observation that most orally active drugs have certain physicochemical properties. According to Lipinski's Rule of Five, a compound is more likely to be orally active if it meets the following criteria:
-== Application ==
+* The compound has no more than 5 [[hydrogen bond donors]] (the total number of nitrogen–hydrogen and oxygen–hydrogen bonds).
-Lipinski's Rule of Five is widely applied in the initial screening of chemical libraries to identify compounds with favorable drug-like properties. It is particularly useful in the field of [[computational chemistry]], where it can be used to filter large databases of chemical compounds before synthesis and testing. However, it is important to note that the rule is not absolute; some successful drugs do not meet these criteria, and not all compounds that satisfy these criteria will be successful drugs.
+* The compound has no more than 10 [[hydrogen bond acceptors]] (all nitrogen or oxygen atoms).
+* The molecular weight of the compound is less than 500 [[daltons]].
+* The compound has a [[log P]] (octanol-water partition coefficient) that does not exceed 5.
+These criteria are not strict rules but rather guidelines that help in the design and evaluation of potential drug candidates.
+== Importance in Drug Discovery ==
+Lipinski's Rule of Five is crucial in the early stages of [[drug discovery]] and development. It helps researchers identify compounds with favorable [[pharmacokinetic]] properties, such as absorption, distribution, metabolism, and excretion (ADME). Compounds that violate more than one of these rules are less likely to be orally active.
 == Limitations ==
-While Lipinski's Rule of Five is a valuable tool in drug discovery, it has limitations. The rule does not account for all aspects of a compound's pharmacokinetic profile, such as its [[metabolism]], [[toxicity]], or [[target]] specificity. Additionally, the rule is less applicable to certain types of drugs, such as [[biologics]], which are typically larger molecules that do not adhere to these criteria.
+While Lipinski's Rule of Five is a valuable tool, it has limitations. It does not account for all factors influencing drug absorption and bioavailability, such as [[P-glycoprotein]] efflux and [[metabolic stability]]. Additionally, some drugs that violate the rule are still effective, such as [[antibiotics]], [[antifungals]], and [[natural products]].
-== Extensions and Modifications ==
+== Example: Omeprazole ==
-Over the years, additional rules and modifications have been proposed to complement or refine Lipinski's Rule of Five. These include the [[Veber rules]] for oral bioavailability, which focus on molecular flexibility and polar surface area, and the [[Rule of Three]] for fragment-based drug discovery, which applies more stringent criteria to smaller molecules.
+[[File:Omeprazole.svg|thumb|right|Omeprazole, a proton pump inhibitor, is an example of a drug that follows Lipinski's Rule of Five.]]
+An example of a drug that adheres to Lipinski's Rule of Five is [[omeprazole]], a widely used [[proton pump inhibitor]] for treating [[gastroesophageal reflux disease]] (GERD). Omeprazole has a molecular weight of 345.42 daltons, 1 hydrogen bond donor, 4 hydrogen bond acceptors, and a log P of 3.3, making it compliant with the rule.
-== Conclusion ==
+== Related Pages ==
-Lipinski's Rule of Five remains a fundamental guideline in medicinal chemistry for evaluating the drug-likeness of chemical compounds. While not without its limitations, it provides a useful starting point for identifying promising drug candidates with favorable oral bioavailability characteristics.
+* [[Drug discovery]]
+* [[Pharmacokinetics]]
+* [[Medicinal chemistry]]
+* [[Christopher A. Lipinski]]
+[[Category:Medicinal chemistry]]
 [[Category:Pharmacology]]
-[[Category:Medicinal chemistry]]
-[[Category:Drug discovery]]
-{{Pharmacology-stub}}
-{{Medicine-stub}}